TY - JOUR
T1 - Efficacy of 1-Kestose Supplementation in Patients with Pancreatic Ductal Adenocarcinoma
T2 - A Randomized Controlled Pilot Study
AU - Nakaoka, Kazunori
AU - Ohno, Eizaburo
AU - Kuramitsu, Kento
AU - Kuzuya, Teiji
AU - Funasaka, Kohei
AU - Tochio, Takumi
AU - Fujii, Tadashi
AU - Takahashi, Hideaki
AU - Kondo, Nobuhiro
AU - Miyahara, Ryouji
AU - Hashimoto, Senju
AU - Hirooka, Yoshiki
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/9
Y1 - 2024/9
N2 - Less than half of all patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) respond to chemotherapy, and the prognosis of PDAC is poor, which may be mediated by the gut microbiota. We investigated the clinical improvement effects of 1-kestose, a fructooligosaccharide, on PDAC chemotherapy in this single-center, randomized, controlled pilot trial conducted at Fujita Health University Hospital, which enrolled patients with PDAC. The trial included 1-kestose administration and non-administration groups. The 1-kestose group received 9 g of 1-kestose daily for 12 weeks, and their blood markers, imaging studies, physical findings, and gut microbiota were evaluated. In the 1-kestose administration group, the cancer marker CA19-9 significantly decreased, and there was a reduction in the neutrophil-to-lymphocyte ratio (NLR). There was also suppression of the reduction of albumin levels and of an increase in C-reactive protein. Additionally, Escherichia coli, which typically increases in PDAC, significantly decreased in the 1-kestose group. Thus, 1-kestose altered the gut microbiota and improved the prognostic factors for PDAC. Large-scale, long-term trials of 1-kestose interventions for PDAC are thus warranted to improve the prognosis of PDAC.
AB - Less than half of all patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) respond to chemotherapy, and the prognosis of PDAC is poor, which may be mediated by the gut microbiota. We investigated the clinical improvement effects of 1-kestose, a fructooligosaccharide, on PDAC chemotherapy in this single-center, randomized, controlled pilot trial conducted at Fujita Health University Hospital, which enrolled patients with PDAC. The trial included 1-kestose administration and non-administration groups. The 1-kestose group received 9 g of 1-kestose daily for 12 weeks, and their blood markers, imaging studies, physical findings, and gut microbiota were evaluated. In the 1-kestose administration group, the cancer marker CA19-9 significantly decreased, and there was a reduction in the neutrophil-to-lymphocyte ratio (NLR). There was also suppression of the reduction of albumin levels and of an increase in C-reactive protein. Additionally, Escherichia coli, which typically increases in PDAC, significantly decreased in the 1-kestose group. Thus, 1-kestose altered the gut microbiota and improved the prognostic factors for PDAC. Large-scale, long-term trials of 1-kestose interventions for PDAC are thus warranted to improve the prognosis of PDAC.
KW - 1-kestose
KW - albumin
KW - microbiota
KW - NLR
KW - pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85203626329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85203626329&partnerID=8YFLogxK
U2 - 10.3390/nu16172889
DO - 10.3390/nu16172889
M3 - Article
C2 - 39275204
AN - SCOPUS:85203626329
SN - 2072-6643
VL - 16
JO - Nutrients
JF - Nutrients
IS - 17
M1 - 2889
ER -